Raloxifene, a SERM targets PD-L1: an in-silico study.

Chopra, Chirag; Yodun, Tenzen; Singh, Harpreet; Singh, Bhupender; Singh, Shashank K; Goutam, Umesh

Chopra, Chirag; Yodun, Tenzen; Singh, Harpreet; Singh, Bhupender; Singh, Shashank K; Goutam, Umesh.

Afiliação

Chopra C; School of Bioengineering and Biosciences, Lovely Professional University Phagwara, Punjab, India.
Yodun T; Cancer Pharmacology Division, Indian Institute of Integrative Medicine (CSIR) Jammu, J&K, India.
Singh H; Department of Bioinformatics, Hans Raj Mahila Maha Vidyalaya Jalandhar, Punjab, India.
Singh B; School of Bioengineering and Biosciences, Lovely Professional University Phagwara, Punjab, India.
Singh SK; Cancer Pharmacology Division, Indian Institute of Integrative Medicine (CSIR) Jammu, J&K, India.
Goutam U; School of Bioengineering and Biosciences, Lovely Professional University Phagwara, Punjab, India.

Am J Transl Res ; 15(8): 5206-5215, 2023.

Article em En | MEDLINE | ID: mdl-37692949

Palavras-chave

ADME; PD-L1; Vina; anticancer; autodock; immune checkpoint; in-silico; raloxifene

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am J Transl Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Índia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google